OMCL
Omnicell, Inc.
OMCL has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has a slight edge over OMCL overall, supported by stronger fundamentals.
OMCL Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Strong |
OMCL's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
OMCL PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $34.95 | — |
| Current | 36x | $34.95 | — |
| Cheap | 52x | $49.71 | +42% |
| Fair | 79x | $75.94 | +117% |
| Expensive | 153x | $147 | +320% |
Historical ranges are pointers, not guarantees.
OMCL has the edge over OSCR in the historical PE scenario, which offers more potential upside but is not a forecast.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
OMCL Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| Low |
Analysts expect OMCL's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over OMCL on the outlook, with more favorable revenue expectations.
OMCL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.92 | +100% |
| Q3 2026 | $0.96 | +123% |
| Q2 2026 | $0.84 | +68% |
| Q1 2026 | $0.44 | -4.3% |
| Q4 2025 | $0.04 | -85% |
| Q3 2025 | $0.43 | +$0.82 |
| Q2 2025 | $0.50 | +$0.96 |
| Q1 2025 | $0.46 | +$0.92 |
| Q4 2024 | $0.27 | +$0.72 |
OMCL has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
OMCL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $307.9M | -0.9% |
| Q2 2026 | $312.2M | +7.4% |
| Q1 2026 | $309.9M | +15% |
| Q4 2025 | $314M | +2.3% |
| Q3 2025 | $310.6M | +10% |
| Q2 2025 | $290.6M | +5% |
| Q1 2025 | $269.7M | +9.6% |
| Q4 2024 | $306.9M | +19% |
OMCL's revenue is growing: $308M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 4.8% | +2.2 points |
| Q2 2026 | 10% | +7.6 points |
| Q1 2026 | 5.4% | +9.8 points |
| Q4 2025 | 0.1% | -3.9 points |
| Q3 2025 | 2.6% | +0.3 points |
| Q2 2025 | 2.8% | +1.6 points |
| Q1 2025 | -4.3% | +4.6 points |
| Q4 2024 | 4% | +13 points |
OMCL has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over OMCL on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
OMCL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $21.7M | +17% |
| Q2 2026 | $59.4M | +92% |
| Q1 2026 | $42.1M | +185% |
| Q4 2025 | $22.6M | -52% |
| Q3 2025 | $18.5M | +33% |
| Q2 2025 | $31M | -37% |
| Q1 2025 | $14.8M | -64% |
| Q4 2024 | $47.2M | +61% |
OMCL still generates free cash flow, though less than at its 2020 peak: $146M over the past year.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over OMCL on cash flow, with more consistent year-over-year improvement.
OMCL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +164K shares |
| 1 year | +1.2% | +566K shares |
| 3 years | +1.9% | +871K shares |
| 5 years | -3.9% | -1.9M shares |
| Available history | +8.2% | +3.5M shares |
OMCL has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $61.9M |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
OMCL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.0x | Net Cash |
| Q2 2026 | -0.9x | Net Cash |
| Q1 2026 | -0.6x | Net Cash |
| Q4 2025 | -0.3x | Net Cash |
| Q3 2025 | -0.1x | Net Cash |
| Q2 2025 | -0.6x | Net Cash |
| Q1 2025 | -0.5x | Net Cash |
| Q4 2024 | -0.3x | Net Cash |
OMCL has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over OMCL on leverage, with a lower net debt burden relative to earnings.
OMCL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.4 | Neutral |
| Stochastic | 46.9 | Neutral |
OMCL's weekly RSI is 45 (neutral) and its Stochastic is 47 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
OMCL PE vs Healthcare Sector
| Metric | OMCL | Sector median | Relative |
|---|---|---|---|
| PE | 36x | 26x | 41% above |
| PE % | 0 | 29 | 29 pts below |
OMCL is trading at 36x earnings, a 41% premium to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over OMCL on valuation relative to its sector.
OMCL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $35.7 | 2% below |
| 20 week MA | $36.9 | 5.2% below |
| 50 week MA | $39.6 | 12% below |
| 100 week MA | $36.7 | 4.7% below |
| 200 week MA | $40.9 | 15% below |
OMCL is in a downtrend: it's below all five of its weekly moving averages, and 15% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over OMCL on trend strength, trading above more of its moving averages.
OMCL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $82.5 | $118.2 | +43% |
| 2021 | $118.2 | $175.7 | +49% |
| 2022 | $175.7 | $48.4 | -72% |
| 2023 | $48.4 | $37.6 | -22% |
| 2024 | $37.6 | $44.1 | +17% |
| 2025 | $44.1 | $46.4 | +5.3% |
| 2026 YTD | $46.4 | $35.0 | -25% |
OMCL has finished higher in four of the last six years. It's down 25% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over OMCL on returns for 2026, with the stronger performance.